Osteosarcoma

Softcover Nachdruck of the original 1. Auflage 2016
ISBN: 978-4-431-56677-9
Verlag: Springer Japan

Buch, Englisch, 270 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 486 g

This book reviews the brilliant progress made in the past three decades in clinical outcomes for osteosarcoma patients treated with a multidisciplinary approach, including limb-salvage surgery combined with neoadjuvant multidrug chemotherapy and aggressive management of pulmonary metastasis. Osteosarcoma was a miserable disease for adolescents and young adults until the early 1970s, with a survival rate that was less than 10–15% even after amputation for affected limbs because of the progression of pulmonary metastasis. With the development of neoadjuvant chemotherapy for osteosarcoma, including high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide during the late 1970s and the 1980s, however, the prognosis has dramatically improved. Limb-salvage surgery for patients with extremity osteosarcoma is now a gold-standard surgical procedure for more than 90% of patients with localized disease. Additionally, aggressive pulmonary metastasectomy for patients with lung metastasis fromosteosarcoma has contributed to improvement of their survival. More recently, carbon-ion radiotherapy has also been introduced for patients with unresectable osteosarcoma of the trunk, as in the spine and pelvis. In this volume the author provides valuable descriptions of an important new treatment modality for a multidisciplinary approach for osteosarcoma patients.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Kawai, Akira

Ueda, Takafumi

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Bildgebende Verfahren, Nuklearmedizin, Strahlentherapie Nuklearmedizin, PET, Radiotherapie

Inhaltsverzeichnis

Part I: Basic Research and Experimental Therapy.-
Chapter 1 Genetics of Osteosarcoma.-Chapter 2 Basic Research for Osteosarcoma Lung Metastasis (LM8).-Chapter 3 Immunotherapy for Osteosarcoma.-
Part II: Clinical Features.-Chapter 4 Outcome of Treatment for Osteosarcoma of the Extremities over the Last 20 Years: Report from 11 Referral Centers in Japan.-Chapter 5 Osteosarcoma in the Elderly: Clinical Features and Outcome.-Chapter 6 Prognostic Factors for Osteosarcoma Patients.-
Part III: Chemotherapy.-Chapter 7 Neoadjuvant Chemotherapy Developed in Japan.-Chapter 8 Neoadjuvant Chemotherapy (OOS-A, B, C, D regimens).-Chapter 9 Caffeine-Potentiated Chemotherapy for Osteosarcoma.-
Part IV: Surgery.-Chapter 10 Endoprosthetic Reconstruction for Extremity Osteosarcoma.-Chapter 11 Limb-Salvage Surgery and Reconstruction for Skeletally Immatur Childhood Osteosarcoma: Extendible Endoprostheses.-Chapter 12 Limb-Salvage Surgery for Pelvic OsteosarcomaChapter 13 Management of Postoperative Infection after Limb Salvage Surgery in Osteosarcoma Patients.-
Part V: Surgery: Biological Reconstruction.-Chapter 14 Biological Reconstruction for Extremity Osteosarcoma: Long Term Results and Current Concept of Intraoperative Extracorporeal Irradiated Bone Graft (IORBG).-Chapter 15 Biological Reconstruction for Extremity Osteosarcoma:  Pasteurized Autogenous Bone Graft.-Chapter 16 Biological Reconstruction for Extremity Osteosarcoma: Liquid Nitrogen Treated Tumor-Bearing Bone Graft.-Chapter 17 Biological Reconstruction for Extremity Osteosarcoma: Distraction Osteogenesis Technique.-Chapter 18 Limb-Saving Surgery Using In Situ Preparation (ISP) Method.-
Part VI: Unresectable / Metastatic Disease.-Chapter 19 Carbon Ion Radiotherapy for Unresectable Osteosarcoma of the Trunk.-Chapter 20 Treatment of Osteosarcoma Patients with Pulmonary Metastasis.-Chapter 21 Long-Term Outcomes and Quality of Life (QOL) in Survivors of Pediatric and Adolescent Osteosarcoma.

Über Autor(innen)

Takafumi Ueda, Osaka National Hospital, Orthopaedic Oncology Group, Department of Orthopaedic Surgery
Akira Kawai, National Cancer Center Hospital, Division of Musculoskeletal Oncology